XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 31.05.2024

Das Instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024
The instrument 8VY DK0061031895 SCANDION ONC. DK-,0735 EQUITY is traded ex capital adjustment on 31.05.2024

Das Instrument ZHY KYG989761062 ZHOU HEI YA HLDG -,000001 EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument ZHY KYG989761062 ZHOU HEI YA HLDG -,000001 EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Das Instrument 36M US82489T1043 SHOCKWAVE MEDICAL DL-,001 EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument 36M US82489T1043 SHOCKWAVE MEDICAL DL-,001 EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Das Instrument 0VU1 KYG5700Y2097 LUFAX HLDG.L. A DL-,00001 EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument 0VU1 KYG5700Y2097 LUFAX HLDG.L. A DL-,00001 EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Das Instrument E17 CA2927661025 ENERPLUS CORP. EQUITY wird ex Kapitalmassnahme gehandelt am 31.05.2024
The instrument E17 CA2927661025 ENERPLUS CORP. EQUITY is traded ex capital adjustment on 31.05.2024

Das Instrument 1YG SE0005003654 MENDUS AB EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument 1YG SE0005003654 MENDUS AB EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Das Instrument GDO3 CA77536Q2027 ROGUE RES INC. EQUITY wird cum Kapitalmassnahme gehandelt am 31.05.2024 und ex Kapitalmassnahme am 03.06.2024
The instrument GDO3 CA77536Q2027 ROGUE RES INC. EQUITY is traded cum capital adjustment on 31.05.2024 and ex capital adjustment on 03.06.2024

Treibt Nvidias KI-Boom den Uranpreis?

In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.

Hier klicken

Zeit	Aktuelle Nachrichten
Di	Clean Energy Transition Inc: Clean Energy closes $425,000 private placement
Di	Clean Energy Transition Inc.: TRANSITION.INC Completes Non-Brokered Private Placement of Flow-Through Units	Not for Distribution to U.S. News Wire Services or Dissemination in the United States TORONTO, ON / ACCESSWIRE / December 23, 2024 / Clean Energy Transition Inc. (TSXV:TRAN) ("transition.inc" or the... ► Artikel lesen
26.11.	Clean Energy Transition Inc: Clean Energy says meeting materials available on-line
26.11.	Clean Energy Transition Inc. Announces Availability of Meeting Materials	TORONTO, ON / ACCESSWIRE / November 26, 2024 / Clean Energy Transition Inc. (TSXV:TRAN) ("transition.inc" or the "Company") announces that in connection with the ongoing Canada Post labour strike, the... ► Artikel lesen
12.11.	Clean Energy Transition Inc: Clean Energy estimates Aurora historical resource

Zeit

Aktuelle Nachrichten

Clean Energy Transition Inc: Clean Energy closes $425,000 private placement

Clean Energy Transition Inc.: TRANSITION.INC Completes Non-Brokered Private Placement of Flow-Through Units

Not for Distribution to U.S. News Wire Services or Dissemination in the United States TORONTO, ON / ACCESSWIRE / December 23, 2024 / Clean Energy Transition Inc. (TSXV:TRAN) ("transition.inc" or the...
► Artikel lesen

26.11.

Clean Energy Transition Inc: Clean Energy says meeting materials available on-line

26.11.

Clean Energy Transition Inc. Announces Availability of Meeting Materials

TORONTO, ON / ACCESSWIRE / November 26, 2024 / Clean Energy Transition Inc. (TSXV:TRAN) ("transition.inc" or the "Company") announces that in connection with the ongoing Canada Post labour strike, the...
► Artikel lesen

12.11.

Clean Energy Transition Inc: Clean Energy estimates Aurora historical resource

Zeit	Aktuelle Nachrichten
18.12.	Mendus - Vididencel shines in ALISON trial (ovarian cancer)	Mendus has reported positive top-line data for its Phase I ALISON trial, which is evaluating lead off-the-shelf cancer vaccine, vididencel, in high-grade serous ovarian carcinoma (HGSC). The news corresponds... ► Artikel lesen
17.12.	Edison Group: Edison Issues Report on Mendus (IMMU)	London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel... ► Artikel lesen
08.11.	Mendus AB: Mendus AB Interim Report January - September 2024	Press ReleaseStockholm, Sweden, November 8, 2024"In the third quarter of 2024, Mendus has focused on expanding the clinical development for vididencel in acute myeloid leukemia (AML) and progressing... ► Artikel lesen
27.08.	Mendus - Broad progress across the pipeline	Mendus's Q224 results reflect a period of steady progress across its clinical programmes. For vididencel, the Phase II CADENCE trial (for acute myeloid leukaemia, AML) is now ready to commence patient... ► Artikel lesen
23.08.	Mendus AB: Mendus AB Interim Report January - June 2024	Press ReleaseStockholm, Sweden, August 23, 2024Data Reported in Q2 Confirm that Vididencel Acts as Active Immunotherapy in AMLIn the second quarter of 2024, Mendus reported in-depth immunological data... ► Artikel lesen

Zeit

Aktuelle Nachrichten

18.12.

Mendus - Vididencel shines in ALISON trial (ovarian cancer)

Mendus has reported positive top-line data for its Phase I ALISON trial, which is evaluating lead off-the-shelf cancer vaccine, vididencel, in high-grade serous ovarian carcinoma (HGSC). The news corresponds...
► Artikel lesen

17.12.

Edison Group: Edison Issues Report on Mendus (IMMU)

London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Mendus (OMX: IMMU)Mendus continues to make headway with its lead programme assessing cancer vaccine vididencel...
► Artikel lesen

08.11.

Mendus AB: Mendus AB Interim Report January - September 2024

Press ReleaseStockholm, Sweden, November 8, 2024"In the third quarter of 2024, Mendus has focused on expanding the clinical development for vididencel in acute myeloid leukemia (AML) and progressing...
► Artikel lesen

27.08.

Mendus - Broad progress across the pipeline

Mendus's Q224 results reflect a period of steady progress across its clinical programmes. For vididencel, the Phase II CADENCE trial (for acute myeloid leukaemia, AML) is now ready to commence patient...
► Artikel lesen

23.08.

Mendus AB: Mendus AB Interim Report January - June 2024

Press ReleaseStockholm, Sweden, August 23, 2024Data Reported in Q2 Confirm that Vididencel Acts as Active Immunotherapy in AMLIn the second quarter of 2024, Mendus reported in-depth immunological data...
► Artikel lesen

Zeit	Aktuelle Nachrichten
30.08.	Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S	As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser to Vator Securities AB. This information is distributed at the request of the Certified Adviser, Västra Hamnen Corporate... ► Artikel lesen
18.07.	Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 2	At the request of Scandion Oncology, Scandion Oncology equity rights will be traded on First North Growth Market as from July 19, 2024. Security name: Scandion Oncology TO 2 -------------------------------------- Short... ► Artikel lesen
18.07.	Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 3	At the request of Scandion Oncology, Scandion Oncology equity rights will be traded on First North Growth Market as from July 19, 2024. Security name: Scandion Oncology TO 3 -------------------------------------- Short... ► Artikel lesen
11.07.	Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Scandion Oncology	At the request of Scandion Oncology, the last trading day in Scandion Oncology's paid subscription units will be changed from 2024-07-11 to 2024-07-15. Instrument: Paid subscription units... ► Artikel lesen

Zeit

Aktuelle Nachrichten

30.08.

Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S

As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser to Vator Securities AB. This information is distributed at the request of the Certified Adviser, Västra Hamnen Corporate...
► Artikel lesen

18.07.

Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 2

At the request of Scandion Oncology, Scandion Oncology equity rights will be traded on First North Growth Market as from July 19, 2024. Security name: Scandion Oncology TO 2 -------------------------------------- Short...
► Artikel lesen

18.07.

Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 3

At the request of Scandion Oncology, Scandion Oncology equity rights will be traded on First North Growth Market as from July 19, 2024. Security name: Scandion Oncology TO 3 -------------------------------------- Short...
► Artikel lesen

11.07.

Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Scandion Oncology

At the request of Scandion Oncology, the last trading day in Scandion Oncology's paid subscription units will be changed from 2024-07-11 to 2024-07-15. Instrument: Paid subscription units...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Fr	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN
13.12.	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN
05.12.	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN
27.11.	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN
19.11.	ZHOU HEI YA (01458): NEXT DAY DISCLOSURE RETURN

Zeit

Aktuelle Nachrichten